Publication: Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study.
Loading...
Identifiers
Date
2022
Authors
Quiroga, Borja
Soler, María José
Ortiz, Alberto
Martínez Vaquera, Shaira
Jarava Mantecón, Carlos Jesús
Useche, Gustavo
Sánchez Márquez, María Gabriela
Carnerero, Manuel
Jaldo Rodríguez, María Teresa
Muñoz Ramos, Patricia
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here. Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed. A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (P The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%, suggesting that KT patients require persistent isolation measures and booster doses of a COVID-19 vaccine. Potential differences between COVID-19 vaccines should be explored in prospective controlled studies.
Description
MeSH Terms
Antibodies, Viral
BNT162 Vaccine
COVID-19
COVID-19 Vaccines
Humans
Prospective Studies
Renal Insufficiency, Chronic
SARS-CoV-2
BNT162 Vaccine
COVID-19
COVID-19 Vaccines
Humans
Prospective Studies
Renal Insufficiency, Chronic
SARS-CoV-2
DeCS Terms
CIE Terms
Keywords
COVID-19, SARS-CoV-2, antibodies, humoral response, vaccine